» Articles » PMID: 34007986

Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types

Overview
Journal Endocr Rev
Specialty Endocrinology
Date 2021 May 19
PMID 34007986
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Osteogenesis imperfecta (OI) is a phenotypically and genetically heterogeneous skeletal dysplasia characterized by bone fragility, growth deficiency, and skeletal deformity. Previously known to be caused by defects in type I collagen, the major protein of extracellular matrix, it is now also understood to be a collagen-related disorder caused by defects in collagen folding, posttranslational modification and processing, bone mineralization, and osteoblast differentiation, with inheritance of OI types spanning autosomal dominant and recessive as well as X-linked recessive. This review provides the latest updates on OI, encompassing both classical OI and rare forms, their mechanism, and the signaling pathways involved in their pathophysiology. There is a special emphasis on mutations in type I procollagen C-propeptide structure and processing, the later causing OI with strikingly high bone mass. Types V and VI OI, while notably different, are shown to be interrelated by the interferon-induced transmembrane protein 5 p.S40L mutation that reveals the connection between the bone-restricted interferon-induced transmembrane protein-like protein and pigment epithelium-derived factor pathways. The function of regulated intramembrane proteolysis has been extended beyond cholesterol metabolism to bone formation by defects in regulated membrane proteolysis components site-2 protease and old astrocyte specifically induced-substance. Several recently proposed candidate genes for new types of OI are also presented. Discoveries of new OI genes add complexity to already-challenging OI management; current and potential approaches are summarized.

Citing Articles

TBS as a complementary tool for assessing vertebral fractures and spinal deformity in children and adolescents with osteogenesis imperfecta.

Liu J, Zhang Y, Yu W, Sun L, Hu J, Jiang Y Osteoporos Int. 2025; .

PMID: 39994027 DOI: 10.1007/s00198-025-07423-2.


Complex Analysis of Micronutrient Levels and Bone Mineral Density in Patients with Different Types of Osteogenesis Imperfecta.

Valeeva D, Akhiiarova K, Minniakhmetov I, Mokrysheva N, Khusainova R, Tyurin A Diagnostics (Basel). 2025; 15(3).

PMID: 39941180 PMC: 11817190. DOI: 10.3390/diagnostics15030250.


Identifying rare variants in genes related to bone phenotypes in a cohort of postmenopausal women.

Patino-Salazar J, Ovejero D, Gabernet M, Martinez-Gil N, Alcaide-Consuegra E, Mellibovsky L Osteoporos Int. 2025; .

PMID: 39915337 DOI: 10.1007/s00198-025-07413-4.


Biochemical characterization of collagen I in Warmblood Fragile Foal Syndrome horse lysyl hydroxylase 1 mutation.

Ishikawa Y, Tufa S, Keene D, Bachinger H, Winand N MicroPubl Biol. 2025; 2025.

PMID: 39839713 PMC: 11749069. DOI: 10.17912/micropub.biology.001399.


Crispant analysis in zebrafish as a tool for rapid functional screening of disease-causing genes for bone fragility.

Debaenst S, Jarayseh T, De Saffel H, Bek J, Boone M, Josipovic I Elife. 2025; 13.

PMID: 39817421 PMC: 11737869. DOI: 10.7554/eLife.100060.


References
1.
Jacobsen C, Barber L, Ayturk U, Roberts H, Deal L, Schwartz M . Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res. 2014; 29(10):2297-306. PMC: 4130796. DOI: 10.1002/jbmr.2198. View

2.
Perosky J, Khoury B, Jenks T, Ward F, Cortright K, Meyer B . Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model. Bone. 2016; 93:79-85. PMC: 5077648. DOI: 10.1016/j.bone.2016.09.013. View

3.
Rubinato E, Morgan A, DEustacchio A, Pecile V, Gortani G, Gasparini P . A novel deletion mutation involving TMEM38B in a patient with autosomal recessive osteogenesis imperfecta. Gene. 2014; 545(2):290-2. DOI: 10.1016/j.gene.2014.05.028. View

4.
Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund A . Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients. J Med Genet. 2012; 50(1):21-4. DOI: 10.1136/jmedgenet-2012-101307. View

5.
Rauch F, Cornibert S, Cheung M, Glorieux F . Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007; 40(4):821-7. DOI: 10.1016/j.bone.2006.11.020. View